Role of formulation vehicles in taxane pharmacology

Investigational New Drugs

Volumn 19, Issue 2, 2001, Pages 125-141

  Van Zuylen, Lia ^a   Verweij, Jaap ^a   Sparreboom, Alex ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cremophor EL; Docetaxel; Paclitaxel; Pharmacokinetics; Tween 80

Indexed keywords

CREMOPHOR; CYCLOSPORIN A; DEHYDRODIDEMNIN B; DIAZEPAM; DIDEMNIN A; DOCETAXEL; DRUG VEHICLE; GLYCOPROTEIN P; PACLITAXEL; POLYSORBATE 80; PROPOFOL; TACROLIMUS; TAXANE DERIVATIVE; TENIPOSIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL STRUCTURE; CLINICAL PHARMACOLOGY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MICELLE; NEPHROTOXICITY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; DRUG HYPERSENSITIVITY; DRUG RESISTANCE, MULTIPLE; GLYCEROL; HUMANS; MICELLES; NEOPLASMS; NERVOUS SYSTEM DISEASES; P-GLYCOPROTEIN; PACLITAXEL; POLYSORBATES; SURFACE-ACTIVE AGENTS;

EID: 0035003021     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010618632738     Document Type: Article

References (150)

1. Plant antitumor agents. VI: The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia
2. Taxol: A history of pharmaceutical development and current pharmaceutical concerns
3. Pharmacology and toxicology of Cremophor EL diluent
4. Polyoxyäthylenglycerol triricinoleat 35 DAC 1979
5. Guidelines for administration
6. Safety profile
7. Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies
8. Anaphylactold reactions associated with parenteral cyclosporine use: Possible role of Cremophor EL
9. Hypersensitivity reactions from taxol
10. Hypersensitivity reactions to the taxanes paclitaxel and docetaxel
11. Overview of Taxol safety
12. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
13. Successful parenteral desensitization to paclitaxel
14. Adverse reactions to intravenous anaesthetic induction agents
15. Complement-mediated reactions to diazepam with Cremophor as solvent (Stesolid MR)
16. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study
17. Interrelationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients
18. Histamine release in dogs by Cremophor EL and its derivatives: Oxyethelated oleic acid is the most effective constituent
19. Contact allergenic activity of Tween 80 before and after air exposure
20. 3H]-paclitaxel in rats: A quantitiative autoradiographic study
21. Central nervous system toxicity after liver transplantation: The role of cyclosporine and cholesterol
22. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
23. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel
24. Drugs containing acids, alcohols and esters
25. Potential neurotoxicity of the solvent vehicle for cyclosporine
26. Emusifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E. 115 neuroblastoma
27. Dialyzer associated neurotoxicity due to a change in fatty acid structure
28. Paclitaxel (Taxol) and docetaxel (Taxotere): Not simply two of a kind
29. Cholestasis in the rat by means of intravenous administration of cyclosporine vehicle, CrEL
30. Cholestatic effects of cyclosporin in the rat
31. Effects of cyclosporine on the isolated perfused rat kidney
32. Use of the isolated perfused kidney model to assess the acute pharmacologic effets of cyclosporine and its vehicle, cremophor EL
33. The influence of the cyclosporine vehicle, Cremophor EL, on renal microvascular blood flow in the rat
34. Taxol, taxotere and other new taxanes
35. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability
36. Measurement of CrEL following Taxol: Plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype
37. Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography
38. Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay
39. Linearized colorimetric assay for Cremophor EL: Application to pharmacokinetics after 1-hour paclitaxel infusions
40. Rapid esrerase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice
41. Titrimettic determination of Cremophor EL in aqueous solutions and biofluids: Part 2: Ruggedness of the method with respect to biofiuids
42. Quantitative determination of polysorbate 20 in nasal pharmaceutical preparations by high-performance liquid chromatography
43. The determination of polysorbare 60 in foods
44. Quantitative determination of polysorbate 60 in non-standard salad dressings
45. Determination of polysorbate in ascites fluid from a premature patient
46. Determination of polysorbates in foods by colorimetry with confirmation by infrared spectrophotometry, thin-layer chromatography, and gas-chromatography
47. Analysis of polysorbate and its polyoxyethylated metabolite
48. Cremophor EL pharmacokinetics in a Phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients
49. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel
50. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo
51. Pharmacologic study of Cremophor EL in cancer patients with impaired hepatic function receiving taxol
52. 3H] paclitaxel and Cremophor EL in a patient severely impaired renal function
53. Preparation of carbon-14-labeled polyoxyethylene (20) sorbitan monolaurate and their metabolitic fate in rats
54. Intermediary metabolism of certain polyoxyethylene derivatives in man. I. Recovery of the polyoxyethylene moiety from urine and feces following ingestion of polyoxyethylene (20) sorbitan monooletate and of polyoxyethylene (40) monostearate
55. Physiological activity of nonionic surfactants
56. The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80
57. Physiology and metabolic patterns of non-ionic surfactants
58. Effects of polysorbate 80 on the absorption and distribution of oral methotrexate (MTX) in mice
59. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL
60. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications
61. Fractionation of Cremophor EL delineates components responsible for plasma lipoprotein alterations and multidrug resistance reversal
62. Effect of Cremophor EL on distribution of Taxol to serum lipoproteins
63. Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment
64. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
65. Pharmacokinetics of the taxanes
66. Nonlinear pharmcokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans
67. Clinical pharmacokineties and pharmacodynamics of paclitaxel: A 3-hour infusion versus a 24-hour infusion
68. Phase I trial of Taxol given as a 24-hour infusion every 21 days, responses observed in metastatic melanoma
69. A pharmacokinetic model for micellar encapsulation of paclitaxel in Cremophor EL
70. Tissue distribution, metabolism and excretion of paclitaxel in mice
71. Inhibiton of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL
72. Properties of Cremophor EL micelles probed by fluorescence
73. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
74. Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice
75. Phase I trial of Cremophor EL with bolus doxorubicin
76. Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin
77. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a Phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer
78. A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer
79. Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80
80. Biodistribution and PIDT efficacy of a ketochlorin photosensitizer as a function of the delivery vehicle
81. Role of the carrier solution in cyclosporine phannacokinetics in the baboon
82. Pharmacokinetics of propofol (Diprivan) as an induction agent
83. Tween 80 increases plasma adriamycin concentrations in mice by an apparent reduction of plasma volume
84. Influence of polysorbate 80 (Tween 80) and etoposide (VP-16-213) on the pharmacokinetics and urinary excretion of Adriamycin and its metabolies in cancer patients
85. Docetaxel in combination with doxorubicin as first line chemotherapy of metastatic breast cancer: A Phase I dose finding study
86. The pharmacokinetics of epirubicin and docetaxel in combination in rats
87. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetic of epirubicin in breast cancer patients
88. Taxoids in combination with anthracyclines and other agents: Pharmacokinetic considerations
89. Effect of a detergent on gastro-intestinal absorption of a steroid
90. Effect of polysorbate 80 on the apparent partition coefficient of drugs on their intestinal absorption in the rat: II. Phenobarbital
91. Absorption and excretion of drugs: XXVI. Effect of non-ionic surface-active agents on rectal absorption of sulphonamides
92. Thiotepa pharmacokinefics during intravesical chemotherapy and the influence of Tween 80
93. Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs
94. Reversal of multidrug resistance by surfactants
95. The solvents Cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor
96. The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance
97. Cremophor-EL enhances Taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line
98. Effect of combination of suboptimal concentrations of P-glycoprotein blockers on the proliferation of MDRI gene expressing cells
99. Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles
100. Reversal of multidrug resistance phenotype by surfactants: Relationship to membrane lipid fluidity
101. Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide
102. Pharmacokinetics of paclitaxel in mdrla P-glycoprotein deficient mice after intravenous and oral administration
103. Comparison of cyclosporin A, verapamil, PSC-833 and cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias
104. Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models
105. Clinical relevance of P-glycoprotein expression in hematological malignancies
106. Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and Cremophor EL
107. Differential modulation of P-glycoprotein. The multidrug resistance mediator, by Cremophor in normal versus leukemic hematopoietic cells
108. Effect of Tween-80 on cell killing by etoposide in human lung adenocarcinoma cells
109. Cremophor and Emulphor induced alterations of serum lipids and lipoprotein electrophoretic patterns of dogs
110. Haematopoietic radioprotection by Cremophor EL: A polyethoxylated castor oil
111. Isolation of mast cells from rabbit lung and liver: Comparison of histamine release induced by the hypnotics Althesin and propanidid
112. Study of histamine release induced by acute administration of antitumor agents in dogs
113. Effects of Taxol on blood cells
114. Paclitaxel pharmacokinetics and pharmacodynamics
115. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
116. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression
117. Indirect-response model for the time course of leukopenia with anticancer drugs
118. The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL
119. Differential activity of Cremopbor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro
120. Paclitaxel induced cytotoxicity - The effects of cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein
121. Is Cremophor EL, solvent for paclitaxel, cytotoxic?
122. Treatment of reticulum cell carcinoma in SJL/J mice with Tween 80
123. Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro
124. Cytotoxic studies of paelitaxel (Taxol) in human tumour cell lines
125. Cremophor EL, solvent for paclitaxel, and toxicity
126. The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines
127. Taxol: A review of its preclinical in vivo antitumor activity
128. Study for modifying activity of solvents on antitumor activity of paclitaxel
129. Analysis of exposure times and dose escalation of paclitaxel In ovarian cancer cell lines
130. Antiproliferative effects of paclitaxel (Taxol) on human renal clear cell carcinomas in vitro
131. Effects of paclitaxel with or without Cremophor EL on cellular clonogenic survival and apoptosis
132. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
133. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
134. Prospective assessment of cardiac toxicity during a randomized Phase II trial of doxorubicin and paclitaxel in metastatic breast cancer
135. Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: The Eastern Cooperative Oncology Group experience
136. Sequences of taxol and cisplatin: A Phase I and pharmacologic study
137. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors
138. Pharmacokinetics of cisplatin and Taxotere (docetaxel) and PBL DNA-adduct formation of cisplatin in the sequence Taxotere/cisplatin and cisplatin/Taxotere in a Phase I/II study in solid tumor patients
139. Current sample handling methods for measurement of cisplatin-DNA-adducts in leukocytes in man lead to discrepant results in DNA-adduct levels and DNA-repair
140. Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL
141. Cremophor EL, a widely used parenteral vehicle, is a potent inhibitor of protein kinase C
142. Phase I study of weekly cisplatin and weekly or four weekly taxol in patients with advanced ovarian cancer
143. Pharmacokinetics of paclitaxel and carboplatin in a dose escalating and sequencing study in patients with non-small cell lung cancer: A European Cancer Centre (ECC) trial
144. Clinical pharmacology of carboplatin administered in combination with paclitaxel
145. Randomised, crossover trial to determine the effect of cremophor on the pharmacokinetics and pharmacodynamics or carboplatin-based therapy
146. Phase I and pharmacologic study of sequences of paclitaxel and cyclo-phosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer
147. Sequence-dependent hematological toxicity associated with 3-hour paclitaxel/cyclophosphamide doublet
148. Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients
149. Phase I study of Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel (Abi-007) in solid tumors
150. A dose finding and pharmacokinetic (PK) Phase I study of a new formulation of docetaxel (D) in advanced solid tumors